Comparative Pharmacology
Head-to-head clinical analysis: BALZIVA 28 versus ORTHO NOVUM 7 7 7 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BALZIVA 28 versus ORTHO NOVUM 7 7 7 21.
BALZIVA-28 vs ORTHO-NOVUM 7/7/7-21
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BALZIVA-28 is a combination estrogen-progestin oral contraceptive. Ethinyl estradiol provides estrogenic activity, while levonorgestrel acts as a progestin, primarily suppressing gonadotropin (FSH and LH) release from the pituitary, inhibiting ovulation, and causing changes in cervical mucus and endometrium to reduce sperm penetration and implantation.
Combined hormonal contraceptive; primarily suppresses ovulation via inhibition of gonadotropin release (LH and FSH) from the pituitary. Also induces changes in cervical mucus and endometrium.
One tablet (0.5 mg levonorgestrel and 0.1 mg ethinyl estradiol) orally once daily for 28 days, starting on the first day of menstrual cycle.
One tablet orally once daily for 21 days, followed by 7 days of no tablets. Each tablet contains norethindrone 0.5 mg/0.75 mg/1 mg and ethinyl estradiol 35 mcg, with biphasic or triphasic dosing per cycle.
None Documented
None Documented
2.5 hours; clinically relevant for dosing interval in renal impairment
Ethinyl estradiol: 13-27 hours; norethindrone: 8-14 hours; with multiple dosing, steady state after 5-7 days.
Renal: 50-60% as unchanged drug; fecal: 30-40% as metabolites; biliary: <5%
Renal: <10% unchanged; biliary/fecal: ~50% as metabolites; extensive enterohepatic recirculation.
Category C
Category C
Oral Contraceptive
Oral Contraceptive